We are live on
!
Find out more
VVM
Versant Venture Management Portfolio holdings
AUM
$141M
1-Year Est. Return
190.82%
This Fund
S&P 500
This Quarter
Est. Return
-3.19%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$95M
AUM Growth
-$36.3M
(-28%)
Cap. Flow
-$17.3M
Cap. Flow
% of AUM
-18.23%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
–
Reduced
1
Closed
1
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
+$16.5M |
| 2 |
OPGN
OpGen, Inc
OPGN
|
+$791K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 76.46% |
Similar funds
POIA
MAM
TM
IA
KCM
RB
YEPX
CFGW
Versant Venture Management's Q4 2017 Portfolio in Review
As of Q4 2017, Versant Venture Management held 8 positions worth $95M, down 28% from $131M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Versant Venture Management withdrew a net $17.3M in Q4 2017, closing 1 position and reducing 1 holding. Its most notable exit was OpGen, Inc, an estimated $791K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 76% of assets, up from 66% a quarter earlier.
- Versant Venture Management's biggest Q4 2017 reduction was Audentes Therapeutics, Inc, cutting an estimated $16.5M.
- Versant Venture Management fully exited OpGen, Inc in Q4 2017, selling an estimated $791K.
- Versant Venture Management's ten largest holdings make up 100% of its $95M portfolio in Q4 2017.
- Versant Venture Management opened 0 new positions and closed 1 in Q4 2017.
- Versant Venture Management's portfolio value fell 28% quarter-over-quarter to $95M.
Based on Versant Venture Management's 13F filing for Q4 2017, filed 25 Jan 2018.